Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study.
Park
K
K
Catholic University Kang Nam St. Mary Hospital, Seoul, South Korea.
Ahn
C
C
Bang
B K
BK
Kang
C M
CM
Kim
S I
SI
Kim
S J
SJ
Kim
Y S
YS
Kim
Y S
YS
Koh
Y B
YB
Kwak
J Y
JY
Kwon
O J
OJ
Moon
I S
IS
Moon
J I
JI
D000017:ABO Blood-Group System; D000328:Adult; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000503:physiopathology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D015995:Prevalence; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000017:ABO Blood-Group System; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus